31Mar 2024
The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A

The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A

A groundbreaking study unveils promising results for combating enteric fever, a significant public health concern in regions with poor water and sanitation infrastructure. Researchers report positive outcomes from the first-ever human trial of a bivalent paratyphoid A-typhoid conjugate vaccine (Sii-PTCV). Among 60 participants, both genders were represented, with 95% male and 5% female. Adverse effects were mostly mild and comparable between Sii-PTCV and Typbar-TCV recipients. Sii-PTCV demonstrated robust immunogenicity against both typhoid and paratyphoid antigens, suggesting its potential as a comprehensive defense against enteric fever. These findings offer hope for improved prevention strategies in vulnerable populations.

  • #general medicine

Like

Save

Share